Difference between revisions of "Team:ETH Zurich"
| Line 71: | Line 71: | ||
img.CH { | img.CH { | ||
padding-bottom: 30px; | padding-bottom: 30px; | ||
| + | } | ||
| + | |||
| + | img.CH { | ||
| + | padding-top: 50px; | ||
} | } | ||
| Line 139: | Line 143: | ||
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor | CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor | ||
<center> | <center> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" width="730px"> | + | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND" width="730px"> |
</center> | </center> | ||
</div> | </div> | ||
Revision as of 14:53, 7 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
